Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours
| Autor: | Jawad Manekia, L. J. Medeiros, Rakesh K. Singh, Kenneth Aldape, Bedia A. Barkoh, Ronald Abraham, Mark J. Routbort, Keyur P. Patel, Neelima Reddy, J Veliyathu, RP Luthra, Xinyan Lu |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Cancer Research
DNA Copy Number Variations Ion Proton Biology medicine.disease_cause Ion Torrent Polymerase Chain Reaction DNA sequencing law.invention law Neoplasms medicine Humans Copy-number variation Massively parallel Gene Exome sequencing Polymerase chain reaction In Situ Hybridization Fluorescence solid tumours Genetics Mutation High-Throughput Nucleotide Sequencing Reproducibility of Results Genetics and Genomics Ion semiconductor sequencing DNA mutations Neoplasm Proteins copy number variations Oncology next-generation sequencing |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 |
| Popis: | Background: In a clinical diagnostic laboratory, we evaluated the applicability of the Ion Proton sequencer for screening 409 cancer-related genes in solid tumours. Methods: DNA was extracted from formalin-fixed, paraffin-embedded (FFPE) tissue biopsy specimens of 55 solid tumours (20 with matched normal tissue) and four cell lines and screened for mutations in 409 genes using the Ion Proton system. The mutation profiles of these samples were known based on prior testing using the Ion Torrent Personal Genome Machine (46-gene hotspot panel), Sanger sequencing, or fluorescence in situ hybridisation (FISH). Concordance with retrospective findings and additional mutations were evaluated. Assay sensitivity and reproducibility were established. Gene copy number variations (CNVs) detected were confirmed by molecular inversion probe (MIP) array. Results: The average Ion Proton (409-gene panel) sequencing output per run was 8 gigabases with 128 million sequencing reads. Of the 15,992 amplicons in the 409-gene panel, 90% achieved a minimum average sequencing depth of 100X. In 59 samples, the Ion Proton detected 100 of 105 expected single-nucleotide variants (SNVs) and all expected deletions (n=8), insertions (n=5), and CNVs (n=7). Five SNVs were not detected due to failed amplification of targeted regions. In 20 tumours with paired normal tissue, Ion Proton detected 37 additional somatic mutations, several in genes of high prognostic or therapeutic significance, such as MET, ALK, TP53, APC, and PTEN. MIP array analysis confirmed all CNVs detected by Ion Proton. Conclusions: The Ion Proton (409-gene panel) system was found to be well suited for use in a clinical molecular diagnostic laboratory. It can simultaneously screen 409 genes for a variety of sequence variants in multiple samples using a low input of FFPE DNA with high reproducibility and sensitivity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|